SUTRO BIOPHARMA, INC. (STRO) Return on equity 2018–2024
SUTRO BIOPHARMA, INC. (STRO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-509.0%FY2024 · since FY2018: -26.8% → -509.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -509.0% | -437.5 pp |
| FY2023 | -71.5% | -16.6 pp |
| FY2022 | -54.9% | -13.1 pp |
| FY2021 | -41.8% | -32.1 pp |
| FY2020 | -9.7% | +112.2 pp |
| FY2019 | -121.9% | -95.1 pp |
| FY2018 | -26.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice